Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Exagen Inc.NASDAQ: XGN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 59.0%

Gross margin was 59.0% in Q1 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 58.3%, down 1.0 pp year over year. Over 3 fiscal years it widened by 11.4 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.0%+3.6 pp QoQ
Last fiscal yearDec 2025
58.3%-1.2 pp YoY
LTMMar 2026
58.3%-1.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.1 pp——
1 year-1.2 pp——
3 years+11.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
58.3%
Year-over-year change
-1.2pp

Gross Margin vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 gross margin of 58.3% is the 7th highest of the 11 companies compared; the peer median is 68.0%.
  • Its year-over-year change of -1.0 pp is the 7th highest of 10, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +11.4 pp compares with a peer median of +3.5 pp.
XGN Competitors Peer median
Gross Margin for XGN and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
SMTISanara MedTech Inc.LTM Mar 202691.2% +0.8 pp+4.0 pp
SGHTSight Sciences, Inc.LTM Mar 202686.2% +0.5 pp+3.5 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
MDXHMDxHealth S.A.FY202559.7% -1.5 pp+7.9 pp
XGNExagen Inc.LTM Mar 202658.3% -1.0 pp+11.4 pp
STXSStereotaxis, Inc.LTM Mar 202653.9% +0.5 pp-12.9 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
TKNOAlpha Teknova, Inc.LTM Mar 202633.3% +12.3 pp-9.0 pp
LFCRLifecore Biomedical, Inc.LTM Mar 202631.2% —-3.8 pp
Peer median (excluding XGN) 68.0%+0.5 pp+3.5 pp

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.3M45.56M52.55M55.64M66.58M
Cost of Revenue20.59M24.21M23.09M22.53M27.78M
Gross Profit27.71M21.35M29.46M33.11M38.8M
Gross Margin57.4%46.9%56.1%59.5%58.3%
Research & Development7.24M9.88M4.87M5.38M6.25M
Selling, General & Admin44.54M52.02M47.43M41.37M46.62M
Operating Expenses51.78M67.4M52.29M46.75M52.87M
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
EBITDA(23.1M)(43.66M)(19.15M)(11.15M)(13.46M)
EBITDA Margin-47.8%-95.8%-36.4%-20.0%-20.2%
Operating Income(24.07M)(46.05M)(22.84M)(13.64M)(14.07M)
Operating Margin-49.8%-101.1%-43.5%-24.5%-21.1%
Interest Income16K830K1.52M767K289K
Interest Expense2.63M2.45M2.34M2.23M4.32M
Other Income / Expenses(2.61M)(1.62M)(819K)(1.47M)(5.83M)
Income Before Tax(26.68M)(47.67M)(23.66M)(15.1M)(19.9M)
Pre-Tax Margin-55.2%-104.6%-45.0%-27.1%-29.9%
Income Tax Expense175K(282K)33K12K51K
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Net Margin-55.6%-104.0%-45.1%-27.2%-30.0%
EPS (Basic)(1.68)(2.77)(1.34)(0.83)(0.93)
EPS (Diluted)(1.68)(2.77)(1.34)(0.83)(0.93)
Weighted Avg Shares15.97M17.08M17.68M18.2M21.56M
Weighted Avg Shares (Diluted)15.97M17.08M17.68M18.2M21.56M

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.